{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:30:20Z","timestamp":1784759420487,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.coph.2016.02.013","type":"journal-article","created":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T11:01:00Z","timestamp":1458730860000},"page":"43-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["New approaches to targeting the bone marrow microenvironment in multiple myeloma"],"prefix":"10.1016","volume":"28","author":[{"given":"Sarah","family":"Gooding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire M","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2016.02.013_bib0305","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"Meads","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2016.02.013_bib0310","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature11885","article-title":"Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches","volume":"495","author":"Ding","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.coph.2016.02.013_bib0315","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature11926","article-title":"CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance","volume":"495","author":"Greenbaum","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.coph.2016.02.013_bib0320","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.stem.2013.03.012","article-title":"This niche is a maze; an amazing niche","volume":"12","author":"Hanoun","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.coph.2016.02.013_bib0325","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.immuni.2004.05.001","article-title":"Cellular niches controlling B lymphocyte behavior within bone marrow during development","volume":"20","author":"Tokoyoda","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2016.02.013_bib0330","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1084\/jem.194.1.45","article-title":"A coordinated change in chemokine responsiveness guides plasma cell movements","volume":"194","author":"Hargreaves","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2016.02.013_bib0335","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coi.2015.01.017","article-title":"Differentiation and maintenance of long-lived plasma cells","volume":"33","author":"Kometani","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coph.2016.02.013_bib0340","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0345","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","article-title":"CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy","volume":"113","author":"Azab","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0350","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","article-title":"CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation","volume":"12","author":"Roccaro Aldo","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.coph.2016.02.013_bib0355","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood.V124.21.3483.3483","article-title":"Phase Ib study of the novel anti-CXCR4 antibody ulocuplumab (BMS-936564) in Combination with lenalidomide plus low-dose dexamethasone, or with bortezomib plus dexamethasone in subjects with relapsed or refractory multiple myeloma","volume":"124","author":"Ghobrial","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0360","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2013-07-517136","article-title":"Osteoblastic niche supports the growth of quiescent multiple myeloma cells","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_sbref0365","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2016.02.013_bib0370","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1158\/1535-7163.MCT-13-0310","article-title":"MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma","volume":"12","author":"Gebhard","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.coph.2016.02.013_sbref0375","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nm.3867","article-title":"The cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells","volume":"21","author":"Zhu","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2016.02.013_bib0380","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1158\/0008-5472.CAN-11-2067","article-title":"Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1","volume":"72","author":"Fowler","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.coph.2016.02.013_bib0385","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-11-2212","article-title":"Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects","volume":"18","author":"Reagan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2016.02.013_bib0390","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"San-Miguel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0395","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/cncr.27745","article-title":"Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma","volume":"119","author":"White","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.coph.2016.02.013_bib0400","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/leu.2014.295","article-title":"Diet-induced obesity promotes a myeloma-like condition in vivo","volume":"29","author":"Lwin","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2016.02.013_bib0405","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2009-07-233437","article-title":"Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches","volume":"116","author":"Winkler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0410","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature13034","article-title":"Direct measurement of local oxygen concentration in the bone marrow of live animals","volume":"508","author":"Spencer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coph.2016.02.013_bib0415","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0420","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1038\/bcj.2014.82","article-title":"Hypoxia promotes stem cell-like phenotype in multiple myeloma cells","volume":"4","author":"Muz","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coph.2016.02.013_bib0425","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1182\/blood.V126.23.1286.1286","article-title":"Hypoxia induces Pgp-mediated carfilzomib resistance in multiple myeloma cells and HIF inhibition significantly enhances sensitivity and response to carfilzomib in vivo","volume":"126","author":"Muz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0430","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood.V126.23.4436.4436","article-title":"Tirapazamine as a strategy to overcome hypoxia-induced drug resistance in multiple myeloma","volume":"126","author":"Muz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0435","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood-2010-02-269126","article-title":"Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug","volume":"116","author":"Hu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0440","first-page":"8579","article-title":"Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma (RR MM)","volume":"33","author":"Laubach","year":"2015","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.coph.2016.02.013_sbref0445","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2016.02.013_sbref0450","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1172\/JCI59987","article-title":"Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease","volume":"125","author":"Ersek","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2016.02.013_bib0455","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2013.090977","article-title":"Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells","volume":"99","author":"Noll","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.coph.2016.02.013_sbref0460","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2016.02.013_bib0465","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","article-title":"Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0470","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/nyas.12578","article-title":"The osteoblastic niche in the context of multiple myeloma","volume":"1335","author":"Toscani","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.coph.2016.02.013_bib0475","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2013.10.029","article-title":"Mechanisms governing metastatic dormancy and reactivation","volume":"155","author":"Giancotti","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.coph.2016.02.013_bib0480","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bone.2010.07.005","article-title":"Dysregulation of developmental pathways in bone metastasis","volume":"48","author":"Sethi","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.coph.2016.02.013_bib0485","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/leu.2013.6","article-title":"Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes","volume":"27","author":"Colombo","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2016.02.013_bib0490","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/leu.2013.27","article-title":"Anti-notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4\/SDF-1","volume":"27","author":"Mirandola","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2016.02.013_bib0495","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2015.07.048","article-title":"Notch signaling: an emerging therapeutic target for cancer treatment","volume":"369","author":"Yuan","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.coph.2016.02.013_bib0500","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coph.2016.02.013_bib0505","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.02.013_bib0510","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1182\/blood.V126.23.119.119","article-title":"Anti-sclerostin treatment prevents multiple myeloma induced bone loss and reduces tumor burden","volume":"126","author":"Reagan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0515","doi-asserted-by":"crossref","first-page":"e9870","DOI":"10.1371\/journal.pone.0009870","article-title":"Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth","volume":"5","author":"Takeuchi","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coph.2016.02.013_bib0520","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coph.2016.02.013_bib0525","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood-2008-08-174300","article-title":"Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin\/TCF signaling","volume":"113","author":"Qiang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0530","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2011-12-396853","article-title":"Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma","volume":"120","author":"Tai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0535","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1038\/bcj.2015.46","article-title":"Targeting the Pim kinases in multiple myeloma","volume":"5","author":"Keane","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coph.2016.02.013_bib0540","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood.V126.23.377.377","article-title":"Combination treatment of the Bruton's tyrosine kinase inhibitor ibrutinib and carfilzomib in patients with relapsed or relapsed and refractory multiple myeloma: initial results from a multicenter phase 1\/2b study","volume":"126","author":"Chari","year":"2015","journal-title":"Blood"},{"issue":"Suppl. 3","key":"10.1016\/j.coph.2016.02.013_bib0545","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/j.clml.2015.07.235","article-title":"Ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: results from a multicenter phase 2 trial","volume":"15","author":"Richardson","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.coph.2016.02.013_bib0550","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood.V124.21.301.301","article-title":"Phase 1 study update of the novel pan-pim kinase inhibitor LGH447 in patients with relapsed\/refractory multiple myeloma","volume":"124","author":"Raab","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0555","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coph.2016.02.013_bib0560","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.V122.21.1959.1959","article-title":"Administration of an oral PDE5 inhibitor, tadalafil in conjunction with a lenalidomide containing regimen in patients with multiple myeloma","volume":"122","author":"Rudraraju","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0565","doi-asserted-by":"crossref","first-page":"I107","DOI":"10.1136\/ard.58.2008.i107","article-title":"Immunomodulation by thalidomide and thalidomide analogues","volume":"58","author":"Corral","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2016.02.013_bib0570","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood-2010-04-278432","article-title":"The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy","volume":"117","author":"Hsu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0575","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2014.46","article-title":"A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib","volume":"28","author":"Ray","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2016.02.013_sbref0580","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2016.02.013_bib0585","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V126.23.1838.1838","article-title":"First interim results of a phase I\/II study of lenalidomide in combination with anti-PD-1 monoclonal antibody MDV9300 (CT-011) in patients with relapsed\/refractory multiple myeloma","volume":"126","author":"Efebera","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0590","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood.V126.23.505.505","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): keynote-023","volume":"126","author":"San Miguel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0595","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1182\/blood.V126.23.506.506","article-title":"A phase II study of anti PD-1 antibody pembrolizumab, pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"126","author":"Badros","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.coph.2016.02.013_bib0600","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1182\/blood.V126.23.4218.4218","article-title":"Blockade of PD-1 in combination with dendritic cell\/myeloma fusion cell vaccination following autologous stem cell transplantation is well tolerated, induces anti-tumor immunity and may lead to eradication of measureable disease","volume":"126","author":"Rosenblatt","year":"2015","journal-title":"Blood"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489216300200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489216300200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T17:40:50Z","timestamp":1600364450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489216300200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":60,"alternative-id":["S1471489216300200"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2016.02.013","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New approaches to targeting the bone marrow microenvironment in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2016.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}